You are here

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Healthcare Corporation MEDOC Medical Dock&Clinic
Nagoya, Aichi, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Hypercholesterolemia, Angina Pectoris
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject with both hypertension and hypercholesterolemia must meet the following (1),
and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

- Subject with both angina pectoris and hypercholesterolemia must meet the following
(1), and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and who meet the following criteria; Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who need three or more multi-antihypertensive therapies to achieve the target
BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is
defined as systolic blood pressure

- Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ?
160 mg/dL even though Atorvastatine 10 mg has administrated

NCT01190007
Pfizer
Completed
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT01897740
All Genders
10+
Years
Moscow,
Hypercholesterolemia Coronary Artery Disease
NCT02565615
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT00878943
All Genders
18+
Years
Multiple Sites
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Hypertension
  • Hypercholesterolemia
  • Angina Pectoris
Drug: Caduet
One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Experimental: Caduet
Intervention: Drug: Caduet
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
159
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject with both hypertension and hypercholesterolemia must meet the following (1), and the following (2) or (3):
  • (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0)
  • (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
  • (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ? 160 mg/dL, LDL-C < 250 mg/dL, and TG < 400 mg/dL at Week -2
  • Subject with both angina pectoris and hypercholesterolemia must meet the following (1), and the following (2) or (3):
  • (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and who meet the following criteria; Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0), and subjects with clinically stable of angina pectoris
  • (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
  • (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ? 160 mg/dL, LDL-C < 250 mg/dL, and TG < 400 mg/dL at Week -2

Exclusion Criteria:

  • Subjects who need three or more multi-antihypertensive therapies to achieve the target BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is defined as systolic blood pressure < 140mmHg and diastolic blood pressure < 90 mmHg.
  • Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ? 160 mg/dL even though Atorvastatine 10 mg has administrated
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01190007
A3841064
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now